Pharmaceuticals · Biotechnology · NSE: RUBICON · data 2026-10-30

Rubicon Research Limited

₹1,610.5+3.28% on 30 OctHealth: Strong 7/10

Feb 2026Low ₹747.6 · High ₹1,860.6+105.3%

In plain words

Price: 15.2% below its 52-week high of ₹1,899.

Delivery: 51.8% of traded shares were kept for delivery over the last 10 sessions, against 49.5% over the last 60.

A description of the data, not a recommendation.

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,610.5

Market cap

₹25,835 cr

P/E

92.7

P/B

—

ROE

27.0%

ROCE

32.4%

Debt / equity

0.24

Dividend yield

0.10%

1-year return

168.0%

52-week high

₹1,899

52-week low

₹607.15

Operating margin

20.6%

Growth

Revenue (last 12 months)	₹1,936 cr
Net profit (last 12 months)	₹288 cr
Sales growth, 3 years (yearly)	64.7%
Profit growth, 3 years (yearly)	—

Smart-money activity

27/100 · Neutral over the last ~60 sessions, data 2026-10-30

Delivery vs usual 7/30: Delivery 53.7% over the last 20 sessions vs 44.8% in the 40 before (1.2x); shares delivered per day 0.56x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
Mutual fund holding 7/15: 3 schemes hold it, about ₹268 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
Accumulation evidence 8/15: Verdict "Building", sustained score 43/100.
Promoter pledges 5/5: No promoter pledge filings in 90 days.

A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.

Story so far

● Dividend

7 Aug 26Dividend Dividend ₹1.5 (ex-date) +4.1% next session

From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.

Common questions

Is Rubicon Research Limited debt-free?

Its latest reported debt-to-equity ratio is 0.24.

What is Rubicon Research Limited's P/E ratio?

About 92.7, based on the last 12 months' earnings and a price of ₹1,610.5 (data 2026-10-30).

What is the 52-week high and low of Rubicon Research Limited?

The 52-week high is ₹1,899 and the 52-week low is ₹607.15.

Mutual funds holding Rubicon Research Limited

From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹268 cr; funds that hold it outside their top holdings may not be listed.

Scheme	Fund house	% of fund	Value
SBI MultiCap Fund	SBI Mutual Fund	1.14%	₹267 cr
Mirae Asset BSE Select IPO ETF	Mirae Asset Mutual Fund	0.78%	₹0 cr
Mirae Asset Nifty 500 Healthcare ETF	Mirae Asset Mutual Fund	0.43%	₹0 cr

Similar companies

Anthem Biosciences Limited (ANTHEM) · Akums Drugs and Pharmaceuticals Limited (AKUMS) · Fermenta Biotech Ltd (FERMENTA) · Fabtech Technologies Limited (FABTECH) · Haleos Labs Ltd. (HALEOSLABS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open RUBICON in NSE Scanner →